RESEARCH ARTICLE

Longitudinal proteomic investigation of COVID-19 vaccination

  • Yingrui Wang 1,2,3,4 ,
  • Qianru Zhu 6 ,
  • Rui Sun 1,2,3,4 ,
  • Xiao Yi 1,2,3,4 ,
  • Lingling Huang 5 ,
  • Yifan Hu 5 ,
  • Weigang Ge 5 ,
  • Huanhuan Gao 1,2,3,4 ,
  • Xinfu Ye 5 ,
  • Yu Song 7 ,
  • Li Shao 6,8 ,
  • Yantao Li 5 ,
  • Jie Li , 9,10 ,
  • Tiannan Guo , 1,2,3,4 ,
  • Junping Shi , 6,11
Expand
  • 1. iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, China
  • 2. Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, China
  • 3. Research Center for Industries of the Future, Westlake University, 600 Dunyu Road, Hangzhou 310030, China
  • 4. Center for Infectious Disease Research, Westlake University, 18 Shilongshan Road, Hangzhou 310024, China
  • 5. Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou 310024, China
  • 6. Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
  • 7. The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China
  • 8. Medical college of Hangzhou Normal University, Hangzhou 311121, China
  • 9. Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
  • 10. Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing 210093, China
  • 11. Department of Infectious and Hepatology Diseases, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
lijier@sina.com
guotiannan@westlake.edu.cn
20131004@hznu.edu.cn

Received date: 01 Nov 2022

Accepted date: 28 Dec 2022

Copyright

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.

Abstract

Although the development of COVID-19 vaccines has been a remarkable success, the heterogeneous individual antibody generation and decline over time are unknown and still hard to predict. In this study, blood samples were collected from 163 participants who next received two doses of an inactivated COVID-19 vaccine (CoronaVac®) at a 28-day interval. Using TMT-based proteomics, we identified 1,715 serum and 7,342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed two sets of potential biomarkers (seven from serum, five from PBMCs) at baseline using machine learning, and predicted the individual seropositivity 57 days after vaccination (AUC = 0.87). Based on the four PBMC’s potential biomarkers, we predicted the antibody persistence until 180 days after vaccination (AUC = 0.79). Our data highlighted characteristic hematological host responses, including altered lymphocyte migration regulation, neutrophil degranulation, and humoral immune response. This study proposed potential blood-derived protein biomarkers before vaccination for predicting heterogeneous antibody generation and decline after COVID-19 vaccination, shedding light on immunization mechanisms and individual booster shot planning.

Cite this article

Yingrui Wang , Qianru Zhu , Rui Sun , Xiao Yi , Lingling Huang , Yifan Hu , Weigang Ge , Huanhuan Gao , Xinfu Ye , Yu Song , Li Shao , Yantao Li , Jie Li , Tiannan Guo , Junping Shi . Longitudinal proteomic investigation of COVID-19 vaccination[J]. Protein & Cell, 2023 , 14(9) : 668 -682 . DOI: 10.1093/procel/pwad004

1
Ai J, Guo J, Zhang H et al. Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discov 2022;8:114.

DOI

2
Arunachalam PS, Scott MKD, Hagan T et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 2021;596:410–416.

DOI

3
Bi X, Liu W, Ding X et al. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19. Cell Rep 2021;38:110271.

DOI

4
Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res 2013;52:446–464.

DOI

5
Brannagan TH 3rd, Auer-Grumbach M, Berk JL et al. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis 2021;16:204.

DOI

6
C DA-M, Couto AES, Campos LCB et al. MMP-2 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients. Biomed Pharmacother 2021;142:112067.

DOI

7
Chen TQ, Guestrin C. XGBoost: a scalable tree boosting system. Kdd’16: Proceedings of the 22nd Acm Sigkdd International Conference on Knowledge Discovery and Data Mining, 2016, 785–794.

DOI

8
Chen Y, Yin S, Tong X et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clin Microbiol Infect 2022;28:410–418.

DOI

9
Costa Clemens SA, Weckx L, Clemens R et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022;399:521–529.

DOI

10
Davey A, McAuley DF, O’Kane CM. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J 2011;38:959–970.

DOI

11
de Souza JG, Starobinas N, Ibanez OCM. Unknown/enigmatic functions of extracellular ASC. Immunology 2021;163:377–388.

DOI

12
Falsey AR, Frenck RW Jr,, Walsh EE et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med 2021;385:1627–1629.

DOI

13
Gao H, Zhang F, Liang S et al. Accelerated lysis and proteolytic digestion of biopsy-level fresh-frozen and FFPE tissue samples using pressure cycling technology. J Proteome Res 2020;19:1982–1990.

DOI

14
Guerra-De-Blas PDC, Bobadilla-Del-Valle M, Sada-Ovalle I et al. Simvastatin enhances the immune response against mycobacterium tuberculosis. Front Microbiol 2019;10:2097.

DOI

15
Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000;96:3049–3055.

DOI

16
Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf 2013;14:7.

DOI

17
Iizuka Y, Cichocki F, Sieben A et al. UNC-45A Is a nonmuscle myosin IIA chaperone required for NK cell cytotoxicity via control of lytic granule secretion. J Immunol 2015;195:4760–4770.

DOI

18
Kabra NH, Kang C, Hsing LC et al. T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc Natl Acad Sci USA 2001;98:6307–6312.

DOI

19
Karlsson M, Zhang C, Mear L et al. A single-cell type transcriptomics map of human tissues. Sci Adv 2021;7:eabh2169.

DOI

20
Karmaus PW, Shi M, Perl S et al. Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight 2019;4:e131530.

DOI

21
Kramer A, Green J, Pollard J et al. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 2014;30:523–530.

DOI

22
Krause PR, Fleming TR, Peto R et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021;398:1377–1380.

DOI

23
Lee A, Wong SY, Chai LYA et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632.

DOI

24
Liu J, Wang J, Xu J et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov 2021;7:99.

DOI

25
Ma ML, Shi DW, Li Y et al. Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discov 2021;7:67.

DOI

26
Meizlish ML, Pine AB, Bishai JD et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Adv 2021;5:1164–1177.

DOI

27
Messner CB, Demichev V, Wendisch D et al. Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst 2020;11:11–24.e4.

DOI

28
Newman AM, Liu CL, Green MR et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453–457.

DOI

29
Otasek D, Morris JH, Boucas J et al. Cytoscape automation: empowering workflow-based network analysis. Genome Biol 2019;20:185.

DOI

30
Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021;21:475–484.

DOI

31
Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010;125:S41–S52.

DOI

32
Serrador JM, Nieto M, Alonso-Lebrero JL et al. CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood 1998;91:4632–4644.

DOI

33
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184:861–880.

DOI

34
Shen B, Yi X, Sun Y et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 2020;182:59–72.e15.

DOI

35
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516.

DOI

36
Ueland T, Holter JC, Holten AR et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect 2020;81:e41–e43.

DOI

37
van der Graaf R, Browne JL, Baidjoe AY. Vaccine equity: past, present and future. Cell Rep Med 2022;3:100551.

DOI

38
Wang Y, Ning X, Gao P et al. Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. Immunity 2017;46:393–404.

DOI

39
Wang Y, Wang X, Luu LDW et al. Proteomic and metabolomic signatures associated with the immune response in healthy individuals immunized with an inactivated SARS-CoV-2 vaccine. Front Immunol 2022;13:848961.

DOI

40
Xue J-B, Lai D-Y, Jiang H-W et al. Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the Omicron variant. Cell Discov 2022;8:15.

DOI

41
Zeng G, Wu Q, Pan H et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis 2022;22:483–495.

DOI

42
Zhang H, Hu Y, Jiang Z et al. Single-cell sequencing and immune function assays of peripheral blood samples demonstrate positive responses of an inactivated SARS-CoV-2 vaccine. SSRN. 2021.

DOI

43
Zhao X, Li D, Ruan W et al. Effects of a prolonged booster interval on neutralization of omicron variant. N Engl J Med 2022;386:894–896.

DOI

44
Zhou Y, Zhou B, Pache L et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10:1523.

DOI

Outlines

/